Chronic Kidney Disease (CKD) Challenges and New Solutions
PREVALENCE OF CKD ACROSS THE US
CKD MORBIDITY/MORTALITY
Estimated prevalence, CKD, U.S. population, 2015-2030
13.2%
14.4%
16.7%
Current CKD Prevalence for Age >65 yo
44%
SOURCES:
> Hoerger TJ et al., American Journal of Kidney Diseases, March 2015 > Braun LA et al., International Journal of Nephrology and Renovascular Disease 2012:5 151–163 > Centers for Disease Control and Prevention, National Center for Health Statistics. Deaths: Final Date for 2011. www.cdc.gov > U.S. Renal Data System. USROS 2010 Annual Report; 2:219
> 2014 USRDS Annual Data Report; Volume 1 – CKD > Hoerger TJ et al. Am J Kidney Dis. 2015;65(3):403-411, JAMA, SEER Cancer Statistics > United States Renal Data System’s 2010 Annual Data Report and 2011 Annual Data Report. > Braun LA et al., International Journal of Nephrology and Renovascular Disease 2012:5 151–163
> 2013 USRDS Annual Data Report; Volume 2 > 2014 USRDS Annual Data Report; Volume 1 – CKD > Source: U.S. Renal Data System, 2005-2012. http://www.usrds.org/2014/view/v2_02.aspx > Personal communication with Navdeep Tangri, MD, FRCPC; Tangri N et al. JAMA. 2016;315(2):164-174; Lee et al. BMC Health Services Research 2012, 12:252; Viewics analysis
> Personal communication with Navdeep Tangri, MD, FRCPC; Tangri N et al. JAMA. 2016;315(2):164-174; Viewics analysis > JAMA. 2016;315(2):164-174.
Leading cause of death in America9th
mortality ratein the first year of dialysis
23%
CKD patients’ rate of hospital readmissions40% higher
only to heart disease in lifetime incidence risk of morbidity (at age 30 in 2015)
2nd
Heart disease, males* 60.3
Heart disease, females* 55.6
CKD 54.1
Cancer, all sites, males 42.8
Cancer, all sites, both sexes 40.0
Cancer, all sites, females 37.6
HIGH GROWTH RATE
COSTS
SUBOPTIMAL CKD CARE
VIEWICS’ NEW SOLUTION FOR CKD
VIEWICS CKD MANAGEMENTTM
POTENTIAL COST SAVINGS
The incidence of recognized CKD in people ages 65
and older more than doubled between 2000 and 2008.
Approximate Medicare spending forEnd Stage Renal Disease in 2015
$56 billion
$ $$
$$
Approximate Medicare spending per person for hemodialysis patients in 2015
$98,000How much more Medicare renal failure patients cost compared to the average
Medicare population
5x
Patient awareness for those with Stages 1-3 CKD
Renal failure patients who saw a nephrologist in the prior year
10%<
33%Amount of dialysis patients who used the
access port associated with the best outcomes in 2011 (a fistula)
16%
Uses an algorithm that combines laboratory tests, age, and gender to predict a patient’s risk of renal failure
End Stage Renal Disease (ESRD) Risk Score+ + =Age
Validated as accurate in more than
720,000 patients, 30 countries
Viewics is implementing the predictive analytics application to automatically deliver the risk score to clinicians and issue customized, educational reports to patients and clinicians.
Approximate full potential savings for U.S. population of CKD Stage 3 and 4 using Viewics CKD ManagementTM
To learn more visit www.renalrisk.com
Approximate cost savings per Stage 4 patient per year using Viewics CKD ManagementTM
$15B
Incorrect Patient ClassificationViewics CKD ManagementTM can help
rectify misclassification of Stage 4 CKD patients into Stage 3 patients due to
inappropriate staging
$5,600
13.2%Estimated prevalence, CKD, U.S. population
2000 2008
Ontario, Canadawill begin requiring the Risk Score in order to receive reimbursement for late stage CKD beginning in April 2016
30%
stage 1
stage 2
stage 3
stage 4
2015
2020
2030
Top Related